Citigroup Inc (NYSE:C) traded up 0.16% during mid-day trading on Monday, hitting $66.80. 13,379,742 shares of the company’s stock traded hands. The stock has a market cap of $183.92 billion, a PE ratio of 13.46 and a beta of 1.48. The firm’s 50-day moving average price is $62.66 and its 200-day moving average price is $60.18. Citigroup has a one year low of $42.50 and a one year high of $68.91.
Citigroup Inc. has chosen Frankfurt as its newest trading hub in the European Union and plans to present that option to its board of directors this week for approval, according to a person with knowledge of the decision.
The choice to expand the bank’s existing broker-dealer in the German city means it will create between 150 and 250 new roles there, said the person, who asked not to be identified talking about internal policies. It’s yet to be decided if the jobs will be filled by moving existing employees or by hiring locally, and it’s likely to be some combination, the person said.
The location, where Citigroup already has about 350 employees, is predictable to handle some of the trading activities presently done in London, though the U.K. capital will remain the headquarters for Europe, the Middle East and Africa, the person said. Sky News stated the decision on Monday. (Source: Bloomberg)
BidaskClub cut shares of Citigroup Inc. (NYSE:C) from a buy rating to a hold rating in a report published on Wednesday morning.
Shares of VF Corp (NYSE:VFC) traded up 0.32% during mid-day trading on Monday, reaching $56.20. 5,300,916 shares of the company’s stock traded hands. The firm’s 50 day moving average price is $54.59 and its 200-day moving average price is $53.64. V.F. Corporation has a 12-month low of $48.05 and a 12-month high of $65.20. The stock has a market cap of $22.51 billion, a price-to-earnings ratio of 22.91 and a beta of 0.77.
V.F. Corporation (NYSE:VFC) was upgraded by equities research analysts at TheStreet from a “c+” rating to a “b-” rating in a note issued to shareholders on Thursday.
Cara Therapeutics Inc (NASDAQ:CARA) opened at $15.25 on Monday. Cara Therapeutics has a one year low of $4.75 and a one year high of $28.50. The company’s market cap is $501.58 million. The stock has a 50 day moving average price of $18.44 and a 200 day moving average price of $15.55.
Cara Therapeutics, Inc. (CARA)’s stock had its “buy” rating reaffirmed by analysts at Stifel Nicolaus in a report issued on Friday, June 23rd, MarketBeat.com reports. They presently have a $20.00 price target on the biopharmaceutical company’s stock, down from their previous price target of $24.00. Stifel Nicolaus’ price objective indicates a potential upside of 29.71% from the stock’s current price.
Shares of Cognizant Technology Solutions Corp (NASDAQ:CTSH) opened at $68.78 on Monday. Cognizant Technology Solutions Corporation has a 12 month low of $45.44 and a 12 month high of $69.00. The firm has a 50 day moving average price of $66.43 and a 200-day moving average price of $60.07. The firm has a market cap of $40.58 billion, a PE ratio of 25.06 and a beta of 1.16.
Columbia Asset Administration cut its position in Cognizant Technology Solutions Corporation (NASDAQ:CTSH) by 13.8% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 4,050 shares of the information technology service provider’s stock after selling 650 shares during the period. Columbia Asset Administration’s holdings in Cognizant Technology Solutions Corporation were worth $241,000 as of its most recent filing with the SEC.